Selective Release of anti–TB Drugs Complex from Smart Copolymeric Bioactive nano–carriers

Authors

  • Alejandro Arredondo–Penaranda 1Grupo de Nuevos Materiales y Espectroscopia Supramolecular. Departamento de Química–Física,Facultad de Ciencia y Tecnología (Campus Leioa). Bilbao 48010, Spain.
  • Luis Guillermo Guerrero–Ramirez Departamento de Química, Universidad de Guadalajara, Centro Universitario de Ciencias Exactas e Ingenierías. Guadalajara Jalisco, México
  • Maria Dolores Blanco Gaitan Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad Complutense de Madrid. Madrid (Spain)
  • Eduardo Mendizabal Departamento de Química, Universidad de Guadalajara, Centro Universitario de Ciencias Exactas e Ingenierías. Guadalajara Jalisco, México
  • Issa Katime 1Grupo de Nuevos Materiales y Espectroscopia Supramolecular. Departamento de Química–Física, Facultad de Ciencia y Tecnología (Campus Leioa). Bilbao 48010, Spain.

DOI:

https://doi.org/10.13171/mjc.2.1.2012.09.08.17

Abstract

Smart nano–copolymeric matrices have been employed to load and release anti tuberculosis (anti –TB) drugs combinated complexes of Ethambutol (EMB), Isoniazid (INH), Rifampicin (RMP) and Pyrazinamide (PZA). Copolymeric nanocarriers were synthesized using a microemulsion polymerization method previously reported. These nanocarriers can show selective swelling–collapse response under changes in local environments such a temperature, pH, solvent composition and electrical stimuli. The employ of these kinds of systems permits a controlled and selective delivery and release on specific human tissues. High Performance Liquid Chromatography technique was used to allow the detection of combinated mixtures of different active principles of anti–TB drugs using an acetonitrile mobile phase at 0.5 mL/min of flow rate whit a Spherisorb ODS2, C18 column. The results obtained suggest that the employ of smart nanohydrogels is a novel method in several tuberculosis therapies.

References

R.F. Jacobs, “Multiple–drug–resistant tuberculosisâ€. Clin Infect Dis 1994; 19:1–10.

K. Neville, A. Bromberg, R. Bromberg, S. Bonk, B.A. Hanna, W.N. Rom, “The Third Epidemic–Multidrug–Resistant Tuberculosisâ€. Chest 1994; 105: 45–48.

A. Telenti, “Genetics of drug resistant tuberculosisâ€. Thorax 1998; 53: 793–797.

Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998; 53: 536–548.

A. Rattan, A. Kalia, N. Ahmad “Multidrug–resistant Mycobacterium tuberculosis: molecular perspectivesâ€. Emerg Infect Dis. 4, 1998, 195–209.

R. Pandey, G.K. Khuller, “Oral nanoparticle–based antituberculosis drug delivery to the brain in an experimental modelâ€. J. Antimicrobial Chemotherapy, 57, 2006, pp. 1146– 1152; MMWR. Initial therapy for Tuberculosis in the era of multidrug resistance: recommendations of the Advisory Council for the Elimination of Tuberculosis. JAMA 1993; 270: 694–698.

J.H. Kent,The epidemiology of multidrug–resistant tuberculosis in the United States. Med Clin North Am 1993; 77: 1391–1409.

F.M. Gordin, E.T. Nelson, J.P. Matts, D.L. Cohn, J. Ernst, D. Benator, “The impact of human immunodeficiency virus infection on drug–resistant tuberculosisâ€. Am J Respir Crit 1996, Care Med. 154: 1478–1483.

C.A. Peloquin, A.E. Bulpitt, G.S. Jaresko, R.W. Jelliffe, J.M. Childs, D.E. Nix , "Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids". Antimicrob Agents Chemother 1999, 43 (3): 568–72.

K.E. Nnoaham, A. Clarke, "Low serum vitamin D levels and tuberculosis: a systematic review and meta–analysis". Int J Epidemiol, 2008, 37 (1): 113–9.

M. Schechter, R. Zajdenverg, G. Falco, G. Barnes, J. Faulhaber, J. Coberly, R. Moore, R. Chaisson,"Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts". Am J Respir Crit Care Med, 2006, 173 (8): 922–6. doi:10.1164/rccm.200512–1953OC.

R.D. Gosling, L.O. Uiso, N.E. Sam, et al. "The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis". Am J Resp Crit Care Med, 2003, 168: 1342–45. doi:10.1164/rccm.200305–682OC

E. Aktas, R. Durmaz, D. Yang, Z. Yang, "Molecular characterization of isoniazid and rifampin resistance of Mycobacterium tuberculosis clinical isolates from Malatya, Turkey". Microbial Drug Resistance, 2005, 11(2): 94–99. doi:10.1089/mdr.2005.11.94

J.S. Shepitka, C.E. Case, L.E. Donaruma, J. Appl. Polym. Sci., 1983, 28: 3611–3617.

N.V. Ravi Kumar, “Handbook of Particulate Drug Deliveryâ€. 2–Volume Set, American Scientific Publishers, 2008.

L.G. Guerrero–Ramírez, S.M. Nuño–Donlucas, L.C. Cesteros, I. Katime, “Novel Functionalized Nanohydrogels: Synthesis and some applicationsâ€. J. Phys.: Conf. Ser. 127 012010 doi: 10.1088/1742–6596/127/1/012010.

L. Brannon–Peppas, Medical Plastics and Biomaterials, 1997, 4, 34.

Valles E, Durand D, Katime I, Mendizábal E, Puig E, Polym. Bulletin (Berlín), 2000, 44, 109–114

L. Mu, S. S. Feng, J. Controlled Release 2003, 86, 33–48.

C.D. Batich, J. Yan, C. Bucarai Jr. and M. Elsabee, Macromolecules 1993, 26, pp. 4675–4680.

L.G. Guerrero–Ramírez, S.M. Nuño–Donlucas, L.C. Cesteros, I. Katime, “Smart copolymeric nanohydrogels: Synthesis, characterization and properties†Materials Chemistry and Physics, 2008, 112, Issue 3, 1088–1092.

Y. Jiao, N. Ubrich, M. Marchand–Arvier et al., “In vitro and in vivo evaluation of oral heparin–loaded polymeric nanoparticles in rabbitsâ€. Circulation, 2002, 105, 230–5.

A.C. Guyton, “Tratado de Fisiología Médicaâ€. Editorial Elsevier, 2006, Chap. 11, 138–143.

H Pérez, M Escolar, E García, JR Azanza “Fármacos antituberculososâ€, Medicine, 1998, 7(84), 3931–3942.

Downloads

Published

2012-08-09

Issue

Vol. 2 No. 1 (2012)

Section

Polymer Chemistry

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).